Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis and Metrics

Madrigal Pharmaceuticals

NASDAQ: MDGL

$544.78 ▲ +1.43 (+0.26%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap15.79 Bn

P/E-37.80

P/S13.94

Div. Yield0.00

Total Debt (Qtr)340.33 Mn

Revenue Growth (1y) (Qtr)126.84

Add ratio to table…

About

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of therapies for metabolic dysfunction associated steatohepatitis (MASH), a progressive liver disease that can lead to cirrhosis and liver failure. The company's lead product, Rezdiffra (resmetirom), is an oral, once daily thyroid hormone receptor beta agonist approved in the United States and Europe for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis. Beyond Rezdiffra, Madrigal is building a broad pipeline that includes MGL 2086, an oral glucagon like peptide 1 receptor agonist from CSPC Pharmaceuticals; ervogastat, a diacylglycerol O acyltransferase 2 inhibitor from Pfizer; and 6 small interfering RNA programs from Rocure targeting MASH related genes. The company does not own manufacturing facilities and relies on third party contract manufacturers for active pharmaceutical ingredient and finished drug supply.

The company generates revenue principally from the sale of Rezdiffra in the United States and Europe. In 2025, product sales of Rezdiffra amounted to $958.4 million, and quarterly sales were annualizing at more than $1.0 billion by year end. Madrigal secures reimbursement through contracts with commercial insurers and government payers, and distributes the product via specialty pharmacy networks that dispense the medication to patients prescribed by hepatologists, gastroenterologists and endocrinologists. While the company does not currently receive royalties or milestone payments from its licensed pipeline candidates, future commercial success of those programs could provide additional revenue streams. Manufacturing is outsourced to established contract manufacturing organizations such as Evonik for active pharmaceutical ingredient and UPM and Corden for tablet formulation, ensuring a reliable supply chain for commercial demand.

Madrigal Pharmaceuticals occupies a pioneering niche in the MASH treatment arena as the first company to obtain approval for a therapy from both the U. S. Food and Drug Administration and the European Commission for noncirrhotic MASH with moderate to advanced fibrosis. Epidemiology estimates indicate approximately 315,000 diagnosed patients in the United States and around 370,000 in Europe who have MASH with F2 to F3 fibrosis and are under specialist care, representing a sizable addressable market expected to grow as awareness and diagnostic rates improve. Competitors include Novo Nordisk advancing semaglutide for MASH, Inventiva with lanifibranor, Roche with saroglitazar, Eli Lilly with various tirzepatide related programs, and Boehringer Ingelheim exploring endothelin receptor antagonists and other novel mechanisms. Numerous preclinical and clinical programs investigate PPAR agonists, GLP1/glucose dependent polypeptide dual agonists, fibroblast growth factor 21 agonists, farnesoid X receptor modulators and other emerging classes. Madrigal’s competitive edge stems from its first mover advantage, a liver directed mechanism targeting hepatic thyroid hormone receptor beta, and a robust patent portfolio protecting Rezdiffra’s composition of matter and weight based dosing regimen until 2045, providing a lengthy market exclusivity period. The company’s pipeline of complementary agents such as MGL 2086, ervogastat and siRNA molecules aims to enhance efficacy across the broader MASH spectrum and to address patient subsets that may not respond adequately to monotherapy.

The company’s customers are patients living with MASH who receive care from hepatologists, gastroenterologists and endocrinologists, specialists who identify and treat the disease. Madrigal engages these physicians through a field force that provides education on the natural history of MASH, the clinical benefits of Rezdiffra and appropriate prescribing practices. In the United States, the product is distributed via specialty pharmacy networks that deliver the medication directly to patients’ homes or to specialty clinics, while in Europe the company launched in Germany and plans to expand country by country as reimbursement approvals are secured. Payors, including private health insurers and government programs such as Medicare and Medicaid, are customers because they determine coverage and reimbursement levels that affect patient access. To support affordability, Madrigal offers patient assistance programs and co pay coupons for eligible individuals, although availability varies by jurisdiction. Overall, the company’s commercial success depends on reaching the diagnosed patient population, securing favorable payer contracts and maintaining a reliable supply chain via its third party manufacturers.

Investment Thesis

▲ Bull case

The company reports that Rezdiffra penetration remains just under 10% of the 460 000 addressable F2 F3 patients while the diagnosis rate is just over 10% meaning the vast majority of eligible patients are still undiagnosed or untreated. Over the last two years the addressable market grew nearly 50% from 315 000 to 460 000 patients driven by increased awareness and specialist referrals. This expansion suggests that the market is still in its earliest stages and that each percentage point gain in diagnosis or prescribing translates into meaningful incremental sales. With Rezdiffra positioned as the first line oral therapy and no approved alternatives in well compensated cirrhosis the opportunity to capture additional share is substantial.
Madrigal has built a deep pipeline with more than ten programs while spending less than 300 million on business development demonstrating an efficient approach to innovation. The recent in licensing of a clinical stage siRNA asset targeting PNPLA3 adds a genetically tailored mechanism that can be combined with Rezdiffra to potentially improve efficacy in the roughly 30% of F2 F3 patients who are homozygous for the risk allele. Parallel efforts include an oral GLP 1 program designed to induce modest weight loss that may amplify Rezdiffra s antifibrotic effect and several other siRNA and small molecule candidates targeting complementary pathways. This diversified pipeline allows the company to pursue multiple shots on goal and to advance only those combinations that deliver meaningful biomarker improvements in early studies.
Real world data collected from tens of thousands of patients show that Rezdiffra consistently delivers improvements across liver stiffness liver fat liver enzymes LDL cholesterol and Lp(a) beyond what was observed in pivotal trials. Poster presentations at major meetings indicate that nearly 70% of prescribers believe the drug has improved their patients quality of life and nearly 70% plan to increase its use over the next six months. This strong clinician endorsement translates into durable prescribing patterns and helps protect the product from pricing pressure as payers recognize the clinical value. Together these outcomes support a premium positioning and suggest that gross to net discounts may remain stable or even improve as the product becomes the standard of care.
The balance sheet shows roughly 818 million dollars in cash cash equivalents restricted cash and marketable securities providing a ample buffer to fund ongoing pipeline investments and commercial expansion without jeopardizing liquidity. Management expects gross to net discounts to settle in the mid to high 30% range for the remainder of 2026 which is in line with or better than initial guidance despite the uptick in SG&A spend. While profitability is not targeted for 2026 the company anticipates reaching sustainable earnings after 2026 as the sales base scales and incremental margin expands. This financial flexibility combined with a clear path to expand the label into well compensated cirrhosis positions Madrigal to capture long term value that the market may not yet be pricing in.
The company has outlined clear near term catalysts with the Maestro MASH F4C outcomes trial expected to read out in 2027 and the F2 F3 histology driven trial slated for 2028. Positive outcomes from these studies could support an expansion of the label into well compensated cirrhosis and potentially secure full approval across the entire fibrosis spectrum. Such label expansions would not only increase the addressable patient base but also strengthen bargaining power with payers by demonstrating hard outcome benefits. Anticipation of these readouts may already be contributing to investor confidence and could act as a catalyst for re rating the stock if the data meet or exceed expectations.

The company reports that Rezdiffra penetration remains just under 10% of the 460 000 addressable F2 F3 patients while the diagnosis rate is just over 10% meaning the vast majority of eligible patients are still undiagnosed or untreated. Over the last two years the addressable market grew nearly 50% from 315 000 to 460 000 patients driven by increased awareness and specialist referrals. This expansion suggests that the market is still in its earliest stages and that each percentage point gain in diagnosis or prescribing translates into meaningful incremental sales. With Rezdiffra positioned as the first line oral therapy and no approved alternatives in well compensated cirrhosis the opportunity to capture additional share is substantial.
Madrigal has built a deep pipeline with more than ten programs while spending less than 300 million on business development demonstrating an efficient approach to innovation. The recent in licensing of a clinical stage siRNA asset targeting PNPLA3 adds a genetically tailored mechanism that can be combined with Rezdiffra to potentially improve efficacy in the roughly 30% of F2 F3 patients who are homozygous for the risk allele. Parallel efforts include an oral GLP 1 program designed to induce modest weight loss that may amplify Rezdiffra s antifibrotic effect and several other siRNA and small molecule candidates targeting complementary pathways. This diversified pipeline allows the company to pursue multiple shots on goal and to advance only those combinations that deliver meaningful biomarker improvements in early studies.
Real world data collected from tens of thousands of patients show that Rezdiffra consistently delivers improvements across liver stiffness liver fat liver enzymes LDL cholesterol and Lp(a) beyond what was observed in pivotal trials. Poster presentations at major meetings indicate that nearly 70% of prescribers believe the drug has improved their patients quality of life and nearly 70% plan to increase its use over the next six months. This strong clinician endorsement translates into durable prescribing patterns and helps protect the product from pricing pressure as payers recognize the clinical value. Together these outcomes support a premium positioning and suggest that gross to net discounts may remain stable or even improve as the product becomes the standard of care.
The balance sheet shows roughly 818 million dollars in cash cash equivalents restricted cash and marketable securities providing a ample buffer to fund ongoing pipeline investments and commercial expansion without jeopardizing liquidity. Management expects gross to net discounts to settle in the mid to high 30% range for the remainder of 2026 which is in line with or better than initial guidance despite the uptick in SG&A spend. While profitability is not targeted for 2026 the company anticipates reaching sustainable earnings after 2026 as the sales base scales and incremental margin expands. This financial flexibility combined with a clear path to expand the label into well compensated cirrhosis positions Madrigal to capture long term value that the market may not yet be pricing in.
The company has outlined clear near term catalysts with the Maestro MASH F4C outcomes trial expected to read out in 2027 and the F2 F3 histology driven trial slated for 2028. Positive outcomes from these studies could support an expansion of the label into well compensated cirrhosis and potentially secure full approval across the entire fibrosis spectrum. Such label expansions would not only increase the addressable patient base but also strengthen bargaining power with payers by demonstrating hard outcome benefits. Anticipation of these readouts may already be contributing to investor confidence and could act as a catalyst for re rating the stock if the data meet or exceed expectations.

▼ Bear case

Rezdiffra accounts for essentially all of the company s revenue leaving Madrigal highly exposed to any slowdown in adoption or any adverse safety signal that could emerge with broader use. The current penetration is under 10% of the addressable market meaning future growth depends heavily on increasing diagnosis rates and converting specialists to prescribers a process that may be slower than management anticipates. While the addressable market has expanded nearly 50% in two years the pace of growth could decelerate as the pool of undiagnosed patients shrinks and as competing awareness campaigns lose momentum. Any failure to maintain the current trajectory of patient adds would directly translate into lower than expected top line growth and could pressure the stock given the high expectations embedded in the valuation.
SG&A expenses rose sharply in the quarter to 268.5 million reflecting continued investment in the endocrinology field force marketing and direct to consumer campaigns and this level of spending may not be sustainable if sales growth begins to moderate. The company has guided that full year 2026 SG&A will increase compared to 2025 with some choppiness in Q2 due to timing of marketing expenses implying that operating leverage may take longer to materialize than investors expect. High fixed costs combined with a still unprofitable profile mean that any miss on sales could lead to larger than anticipated losses and could erode the cash buffer more quickly than planned. This cost structure raises the bar for achieving profitability and could limit the ability to return capital to shareholders in the near term.
The pipeline while promising remains early stage with most assets still in preclinical or Phase I development and the success of combination strategies is far from guaranteed. The siRNA asset targeting PNPLA3 has only Phase I data showing a reduction in liver fat and there is no proof yet that adding it to Rezdiffra will produce a clinically meaningful antifibrotic benefit in the genetically defined subgroup. Similarly the oral GLP 1 program is only just initiating Phase I studies and its ability to induce weight loss that meaningfully enhances Rezdiffra s effect remains unproven. Until later stage data validate these approaches the pipeline may represent more optionality than near term value and investors could be overestimating the likelihood of successful readouts.
Payer negotiations are still evolving and the gross to net discount guidance of mid to high 30% may prove optimistic if competitors enter the market with lower list prices or if health plans demand larger rebates to maintain formulary placement. The company has noted that gross to net came in better than anticipated in Q1 but expects the range to stay elevated as payer contracting matures suggesting that net price pressure could persist. Any worsening of the discount environment would directly cut into margins and could delay the timeline to profitability beyond the current outlook. Moreover the addressable market size estimates rely on assumptions about disease prevalence and specialist referral patterns that may not hold true in real world settings further clouding the long term sales potential.
The commercial expansion hinges on the assumption that adding specialists such as endocrinologists will generate a proportional increase in prescriptions yet early adoption in new specialties often follows a slower learning curve. Management has noted that endocrinologists are just coming on board and that it may take time for them to integrate Rezdiffra into their typical practice patterns. If the uptake in these newer prescriber groups lags behind expectations the overall patient addition rate could fall short of the steady growth narrative. This would force the company to rely more heavily on its existing gastroenterology and hepatology base which may already be nearing saturation in certain regions.

Rezdiffra accounts for essentially all of the company s revenue leaving Madrigal highly exposed to any slowdown in adoption or any adverse safety signal that could emerge with broader use. The current penetration is under 10% of the addressable market meaning future growth depends heavily on increasing diagnosis rates and converting specialists to prescribers a process that may be slower than management anticipates. While the addressable market has expanded nearly 50% in two years the pace of growth could decelerate as the pool of undiagnosed patients shrinks and as competing awareness campaigns lose momentum. Any failure to maintain the current trajectory of patient adds would directly translate into lower than expected top line growth and could pressure the stock given the high expectations embedded in the valuation.
SG&A expenses rose sharply in the quarter to 268.5 million reflecting continued investment in the endocrinology field force marketing and direct to consumer campaigns and this level of spending may not be sustainable if sales growth begins to moderate. The company has guided that full year 2026 SG&A will increase compared to 2025 with some choppiness in Q2 due to timing of marketing expenses implying that operating leverage may take longer to materialize than investors expect. High fixed costs combined with a still unprofitable profile mean that any miss on sales could lead to larger than anticipated losses and could erode the cash buffer more quickly than planned. This cost structure raises the bar for achieving profitability and could limit the ability to return capital to shareholders in the near term.
The pipeline while promising remains early stage with most assets still in preclinical or Phase I development and the success of combination strategies is far from guaranteed. The siRNA asset targeting PNPLA3 has only Phase I data showing a reduction in liver fat and there is no proof yet that adding it to Rezdiffra will produce a clinically meaningful antifibrotic benefit in the genetically defined subgroup. Similarly the oral GLP 1 program is only just initiating Phase I studies and its ability to induce weight loss that meaningfully enhances Rezdiffra s effect remains unproven. Until later stage data validate these approaches the pipeline may represent more optionality than near term value and investors could be overestimating the likelihood of successful readouts.
Payer negotiations are still evolving and the gross to net discount guidance of mid to high 30% may prove optimistic if competitors enter the market with lower list prices or if health plans demand larger rebates to maintain formulary placement. The company has noted that gross to net came in better than anticipated in Q1 but expects the range to stay elevated as payer contracting matures suggesting that net price pressure could persist. Any worsening of the discount environment would directly cut into margins and could delay the timeline to profitability beyond the current outlook. Moreover the addressable market size estimates rely on assumptions about disease prevalence and specialist referral patterns that may not hold true in real world settings further clouding the long term sales potential.
The commercial expansion hinges on the assumption that adding specialists such as endocrinologists will generate a proportional increase in prescriptions yet early adoption in new specialties often follows a slower learning curve. Management has noted that endocrinologists are just coming on board and that it may take time for them to integrate Rezdiffra into their typical practice patterns. If the uptake in these newer prescriber groups lags behind expectations the overall patient addition rate could fall short of the steady growth narrative. This would force the company to rely more heavily on its existing gastroenterology and hepatology base which may already be nearing saturation in certain regions.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password